EP Patent

EP2159220A1 — Organic compounds

Assigned to Nabriva Therapeutics AG · Expires 2010-03-03 · 16y expired

What this patent protects

Compounds of formula I, which are 14-O-{[(2-(optionally substituted-hydroxy)-cyclohexyl)-sulfanyl]-acetyl}-mutilins further substituted at the cyclohexyl group by an acylated amino group, salts and solvates thereof, pharmaceutical compositions comprising such compounds and their …

USPTO Abstract

Compounds of formula I, which are 14-O-{[(2-(optionally substituted-hydroxy)-cyclohexyl)-sulfanyl]-acetyl}-mutilins further substituted at the cyclohexyl group by an acylated amino group, salts and solvates thereof, pharmaceutical compositions comprising such compounds and their use as a pharmaceutical, e.g. for the treatment of diseases mediated by microbes and for the treatment of inflammation where microbes are mediating said inflammation.

Drugs covered by this patent

Patent Metadata

Patent number
EP2159220A1
Jurisdiction
EP
Classification
—
Expires
2010-03-03
Drug substance claim
No
Drug product claim
No
Assignee
Nabriva Therapeutics AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.